Editing human DNA has entered the public consciousness in a big way in recent years with its increasing use in laboratories—and, in recent news that shocked the scientific community, in embryos—of tools such as CRISPR-Cas9.

Locana, a gene therapy biotech in San Diego, is taking what it describes as a “parallel path” to developing therapeutics that could potentially fix diseases by changing our genetic code through altering DNA’s molecular compatriot, RNA. Tweaking RNA may let scientists avoid some of the concerns swirling around editing DNA—our genetic map—such as the risk that subsequent generations could inherit any gene edits. RNA… Read more »